Liu Pin-Chun, Lin Yi-Sheng, Ou Yen-Chuan, Hsu Chao-Yu, Tung Min-Che, Chiu Ying-Ming
Division of Urology, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung City, Taiwan.
Departments of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan.
PLoS One. 2025 Apr 8;20(4):e0310613. doi: 10.1371/journal.pone.0310613. eCollection 2025.
Prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide and the 5th leading cause of death from cancer for men in Taiwan. The incidence of synchronous metastatic PCa in Taiwan is higher than U.S. and Europe. We aim to present the latest life expectancy (LE), loss of LE, and lifetime cost associated with PCa in Taiwan. The PCa data are based on Taiwan Cancer Registry and National Health Insurance Database. Total 30,207 new cases of PCa were recorded during 2008-2019 nationwide. LE, estimated loss of LE and lifetime cost were stratified by age, cancer stage, Gleason score, grade group and serum PSA level at diagnosis. We compared LE and healthcare cost outcomes between synchronous metastatic PCa patients in 3 age groups. Among the 30,207 new cases, the low to intermediate risk groups, high-risk groups, and regional and metastatic PCa accounted for 54.1%, 13.2%, and 32.6% of cases, respectively. A considerable proportion of synchronous metastatic PCa was noted in Taiwan when compared with the U.S. For synchronous metastatic PCa, the highest LE is 9.22 years for ages 20-64 years, followed by ages 65-74 (8.29 years) and ages 75-89 years (4.58 years). The loss of LE in the three age groups is 13.63, 6.75, and 3.87 years, respectively. The healthcare cost of synchronous metastatic PCa in all age groups is higher than the average cost for PCa patients in Taiwan. This study provides real-world evidence to support health care policy-making and clinical decisions regarding PCa. Due to the high proportion of synchronous metastatic PCa in Taiwan, the findings of this analysis emphasize the importance of early detection of PCa, which can save LE and decrease the total cost burden on the healthcare system.
前列腺癌（PCa）是全球第二大最常被诊断出的癌症，也是台湾男性因癌症死亡的第五大主要原因。台湾同步转移性PCa的发病率高于美国和欧洲。我们旨在呈现台湾PCa相关的最新预期寿命（LE）、预期寿命损失及终生成本。PCa数据基于台湾癌症登记处和国民健康保险数据库。2008年至2019年期间，全国共记录了30207例新的PCa病例。LE、估计的LE损失和终生成本按年龄、癌症分期、 Gleason评分、分级组以及诊断时的血清PSA水平进行分层。我们比较了3个年龄组同步转移性PCa患者的LE和医疗成本结果。在这30207例新病例中，低至中度风险组、高风险组以及局部和转移性PCa分别占病例的54.1%、13.2%和32.6%。与美国相比，台湾同步转移性PCa的比例相当高。对于同步转移性PCa，20至64岁年龄组的最高LE为9.22年，其次是65至74岁（8.29年）和75至89岁（4.58年）。这三个年龄组的LE损失分别为13.63年、6.75年和3.87年。所有年龄组同步转移性PCa的医疗成本均高于台湾PCa患者的平均成本。本研究提供了真实世界的证据，以支持有关PCa的医疗保健政策制定和临床决策。由于台湾同步转移性PCa的比例较高，该分析结果强调了早期检测PCa的重要性，这可以节省LE并减轻医疗系统的总成本负担。
